177Lu-rhPSMA-10.1 Induces Tumor Response in a Patient With mCRPC After PSMA-Directed Radioligand Therapy With 177Lu-PSMA-I&T. (22nd April 2023)

• Record Type: Journal Article
• Authors: Bundschuh, Ralph A.; Pfob, Christian H.; Wienand, Georgine; Dierks, Alexander; Kircher, Malte; Lapa, Constantin
• Is Part Of: Clinical nuclear medicine. Volume 48:Number 4(2023)
• Page Start: 337
• Page End: 338
• Publication Date: 2023-04-22
• Subjects: theranostics -- 177Lu-rhPSMA-10.1 -- prostate cancer -- radiologand therapy; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000004573
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract: 177 Lu-rhPSMA-10.1 is a novel PSMA-targeting radiopharmaceutical that has been optimized in terms of pharmacological and pharmacokinetic properties and may be therefore advantageous in treatment of metastatic castrate-resistant prostate cancer. In this image, we present the case of an 86-year-old man with metastastic castrate-resistant prostate cancer undergoing 177 Lu-PSMA-I&T treatment. After initial partial response to radioligand therapy, another 2 treatment cycles resulted in a rising serum PSA level that could be correlated with increasingly PSMA-positive as well as a new bone lesion. Consequently, the patient was changed to 177 Lu-rhPSMA-10.1 treatment on a compassionate use basis achieving a renewed tumor response.